GENERAL OBJECTIVES – From seizures to genes: how Dravet syndrome is changing the way we treat epilepsy

The theme of our 2019 conference is “From seizures to genes: how Dravet syndrome is changing the way we treat epilepsy”. This event is designed to bring together a range of professionals committed to improving the lives of people with epilepsy, including clinicians, researchers and professionals from the pharmaceutical industry. There will be speaker presentations on the latest advances in epilepsy drug development using Dravet syndrome as an example of how the understanding and treatment of epilepsy has evolved and is constantly evolving over the years. Presentations will include a variety of therapeutic modalities including small molecules, antisense oligonucleotides and gene therapy.

More information

Dravet Syndrome Foundation Spain was founded in 2011 by a group of parents with children affected by this rare disease, a group of impatient patients who do not resign themselves to the course of this disease. Our objective is to facilitate, foster and promote the development of research in the environment of Dravet syndrome in order to progress in the knowledge of its causes, improve its diagnosis and find effective treatments to mitigate and eliminate the adverse effects of this disease.

We encourage all stakeholders in health and medicines R&D to join this conference: policy makers, academics and researchers, pharmaceutical industry and other sectors in healthcare, SMEs and mid-sized enterprises, regulators, representatives of other public-private partnerships and research-funding organisations.

José Ángel Albar. President, Dravet Syndrome Foundation Spain

With the scientific endorsement of the Spanish Society of Neurology
09.00 – 09.30 Opening statements

09.30 – 09.45 Introduction to the program

09.45 – 10.30 Evolution in the diagnostic of rare genetic epilepsies
Moderator: Stephan Auvin, INSERM France

When Before genetics: clinical diagnosis of rare epilepsies
Rocío Sánchez Carpintero, Clínica Universidad de Navarra

The genetic revolution in rare epilepsies
Sara Álvarez, NIMGenetics

10.30 – 11.00 Coffee break

11.00 – 12.30 Treating seizures: symptomatic treatment of Dravet syndrome
Moderator: Antonio Gil-Nagel, Hospital Ruber Internacional

Treatment decisions in pharmacoresistant epilepsy patients
Antonio Gil-Nagel, Hospital Ruber Internacional

The development of Epidiolex
Ángel Aledo, Hospital Ruber Internacional

The development of Fintepla
Stephan Auvin, INSERM France

The development of OV935
Juan Carlos Álvarez Sánchez, HU Virgen de las Nieves

12.30 – 13.30 Lunch break

Moderator: Rubén Hernández, Cima Universidad de Navarra

Targeting Nav1.1-interneurons to restore cognitive and network functions
Jorge Palop, Gladstone Institutes

Gene therapy approaches for Dravet Syndrome
Rajvinder Karda, University College of London

Delivery of the entire SCN1A coding sequence using High-Capacity Adenoviral vectors for the treatment of Dravet syndrome
Ana Ricobaraza, Cima Universidad de Navarra

Restoring gene expression with gene therapy
Jen Seda,Encoded Therapeutics

TANGO technology and its application to Dravet Syndrome: a novel approach to the cause of the disease
Javier Avendaño, Stoke Therapeutics

15.10 – 15.30 Coffee Break

15.30 – 15.50 Patient organizations as partners in drug development

15.50 – 16.30 Open discussions and closure